ERISA as a Barrier for State Health Care Transparency Efforts

Erin C Fuse Brown, Jaime S. King
{"title":"ERISA as a Barrier for State Health Care Transparency Efforts","authors":"Erin C Fuse Brown, Jaime S. King","doi":"10.1017/9781108658867.027","DOIUrl":null,"url":null,"abstract":"To improve health care market dynamics and reduce costs, many states have passed legislation to improve transparency in health care for consumers, regulators, and employers. Significant state-led initiatives include building price transparency tools using data from state all-payer claims databases (APCDs), requiring pharmacy benefit managers to report drug markups and pricing methodologies, increasing provider network transparency, and limiting surprise medical bills from out-of-network providers. Despite robust and salutary state innovation in consumer health care transparency, the federal Employee Retirement Income Security Act’s (ERISA) growing preemptive sweep prevents these state laws from benefiting a growing percentage health care consumers — those covered by self-funded employee health plans. In Gobeille v. Liberty Mutual, the Supreme Court dramatically broadened ERISA’s preemptive reach over state laws imposing data reporting requirements on self-funded plans. The expanding scope of ERISA preemption fundamentally limits the ability of states to protect their citizen-consumers and oversee rising health care costs through health care transparency laws. For transparency initiatives to achieve their maximal effect at the state level, lawmakers must make changes at the federal level. A federal solution could take many forms, ranging from narrow-issue administrative rulemaking to amending ERISA to exempt state transparency laws from preemption. Although federal policy may be necessary for health care transparency efforts to reach all consumers, such a policy should preserve state flexibility and innovation.","PeriodicalId":221919,"journal":{"name":"ERN: National","volume":"77 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ERN: National","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/9781108658867.027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

To improve health care market dynamics and reduce costs, many states have passed legislation to improve transparency in health care for consumers, regulators, and employers. Significant state-led initiatives include building price transparency tools using data from state all-payer claims databases (APCDs), requiring pharmacy benefit managers to report drug markups and pricing methodologies, increasing provider network transparency, and limiting surprise medical bills from out-of-network providers. Despite robust and salutary state innovation in consumer health care transparency, the federal Employee Retirement Income Security Act’s (ERISA) growing preemptive sweep prevents these state laws from benefiting a growing percentage health care consumers — those covered by self-funded employee health plans. In Gobeille v. Liberty Mutual, the Supreme Court dramatically broadened ERISA’s preemptive reach over state laws imposing data reporting requirements on self-funded plans. The expanding scope of ERISA preemption fundamentally limits the ability of states to protect their citizen-consumers and oversee rising health care costs through health care transparency laws. For transparency initiatives to achieve their maximal effect at the state level, lawmakers must make changes at the federal level. A federal solution could take many forms, ranging from narrow-issue administrative rulemaking to amending ERISA to exempt state transparency laws from preemption. Although federal policy may be necessary for health care transparency efforts to reach all consumers, such a policy should preserve state flexibility and innovation.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ERISA是国家卫生保健透明度努力的障碍
为了改善医疗保健市场动态并降低成本,许多州已经通过了立法,以提高消费者、监管机构和雇主在医疗保健方面的透明度。国家主导的重要举措包括,利用国家所有付款人索赔数据库(apcd)的数据建立价格透明度工具,要求药房福利管理人员报告药品加价和定价方法,提高供应商网络的透明度,并限制来自网络外供应商的意外医疗账单。尽管各州在消费者医疗保健透明度方面进行了强有力和有益的创新,但联邦雇员退休收入保障法(ERISA)越来越多的先发制人的打击阻止了这些州法律惠及越来越多的医疗保健消费者——那些自费雇员健康计划的消费者。在Gobeille诉Liberty Mutual案中,最高法院戏剧性地扩大了ERISA对州法律对自备资金计划施加数据报告要求的先发制人的影响力。ERISA优先权范围的扩大从根本上限制了各州保护其公民消费者和通过医疗透明度法律监督不断上升的医疗成本的能力。为了使透明度倡议在州一级达到最大效果,立法者必须在联邦一级进行改革。联邦政府的解决方案可以采取多种形式,从狭隘的行政规则制定到修改ERISA,以使州透明度法免于优先考虑。虽然联邦政策可能是必要的卫生保健透明度努力达到所有消费者,这样的政策应该保持国家的灵活性和创新。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Comparison of Film Tax Credits Across State Lines The Contestation of the Notion of Debt-Trap Diplomacy on Nigeria-China Relations: The Dilemma and Critical Issues Australian Federalism in James Buchanan's Early Work on Fiscal Equity Convergence across Subnational Regions of Bangladesh – What the Night Lights Data Say? The Effects of Local Government Financial Distress: Evidence from Toxic Loans
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1